ESE is grateful to Rhythm Pharmaceuticals
for being a Silver Sponsor of ECE 2026
Please visit them at exhibit booth 12
Sessions at ECE 2026
Satellite symposium
Sunday 10 May 2026, 12:50-14:05 CEST, South Hall 2
Advancing care in rare MC4R pathway diseases - Focus on Bardet-Biedl syndrome (BBS)
Chair: Philip Beales, UK
- Welcome and Introduction, Philip Beales (UK)
- Overview of rare MC4R pathway diseases as a root cause of hyperphagia and obesity, Philip Beales (UK)
- Impact of early-onset obesity and urgency to treat, Matthias Blüher (Germany)
- Real-world evidence in treating Bardet-Biedl syndrome, Pauline Faucher (France)
- Interactive Q&A session, All faculty
Abstracts at ECE 2026
Poster: Recognizing the burden of acquired hypothalamic obesity in craniopharyngioma: cross-country insights from lived experiences to support integrated care across all life stages
Presenting Author: Professor Hanneke van Santen
Poster: Impact of setmelanotide on metabolic index scores in Phase 3 trial participants with acquired hypothalamic obesity
Presenting Author: Professor Hanneke van Santen
Poster: Efficacy and safety of setmelanotide in acquired hypothalamic obesity: results from a double-blind, multicenter, placebo-controlled, randomized Phase 3 trial
Presenting Author: Professor Hanneke van Santen
ePoster: Hyperphagia severity in adult patients with Bardet-Biedl syndrome - a mixed-methods cross-sectional study in the United Kingdom
Presenting Author: Professor Philip Beales
ePoster: Real-world BMI outcomes in adult patients with acquired hypothalamic obesity treated with setmelanotide for up to 9 months in France
Presenting Author: Dr. Pauline Faucher
ePoster: Genotype-phenotype correlation of ophthalmic, renal/genitourinary, neurological and neurodevelopmental manifestations in published cases of Bardet-Biedl syndrome